A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2017; you can also visit the original URL.
The file type is
and Objectives: Clozapine (CLOZ) and levomepromazine (LMP) improve treatment-resistant schizophrenia. The superior efficacy of CLOZ compared with other antipsychotic agents has been attributed to an effect on D1-like and D4 receptors. We examined the binding of LMP, CLOZ and cyamemazine (CMZ), a neuroleptic analog of LMP, to human recombinant dopamine (rDA) receptor subtypes. Methods: Binding studies were performed on frozen membrane suspensions of human rDA receptor subtypes expressed in Sf9doi:10.4321/s0213-61632009000300003 fatcat:ghv47qdlvzhufkaknk6qu36ade